Healwell AI Inc.

Equities

AIDX

CA42249X1006

Healthcare Facilities & Services

Market Closed - Toronto S.E. 04:00:00 2024-07-18 pm EDT 5-day change 1st Jan Change
2.09 CAD 0.00% Intraday chart for Healwell AI Inc. -12.55% +178.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Well Health Launches AI-Powered "Co-pilot" for Cardiologists Powered by HEALWELL AI MT
Well Health Brief: Launching its AI-POWERED Co-pilot for Cardiologists powered by HEALWELL AI MT
WELL Health Gets OK For "Historic" $44 Million Project; Involves HEALWELL AI MT
WELL Health Technologies Corp. Announces Approval for Historic $44 Million Project to Advance AI-powered Tech Enablement for Care Providers CI
Healwell AI Inc. acquired 20% stake in Mci Polyclinic Group Inc. CI
Healwell AI Down 7.5% as it Closes the Purchase of VeroSource Solutions and BioPharma Services MT
Healwell AI Inc. completed the acquisition of Bio Pharma Services Inc. from Think Research Corporation for CAD 15 million. CI
Healwell AI Inc. completed the acquisition of VeroSource Solutions Inc. CI
Healwell AI Backs Musk-founded X.AI With US$2 Million Investment MT
X.AI Corp. announced that it has received $2 million in funding from Healwell AI Inc. CI
Healwell AI Agrees to Buy BioPharma Services For $11.9 Million to Expand Clinical Research Offerings MT
Healwell AI Inc. agreed to acquire 100% stake in Bio Pharma Services Inc. from Think Research Corporation for CAD 14.4 million. CI
Healwell AI Agrees to Buy VeroSource Solutions for $24.5 Million to Add its Cloud-Based Health Data Interoperability Platform MT
Healwell AI Inc. agreed to acquire VeroSource Solutions Inc. for CAD 24.5 million on June 11, 2024. CI
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema MT
HEALWELL AI Unit Partners With Takeda for Rare Disease Evidence Analysis MT
HEALWELL AI Brief: Subsidiary Pentavere Announcing Partnership with Takeda to "Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema" MT
HEALWELL AI Appoints Anthony Lam as its Chief Financial Officer MT
HEALWELL AI Brief: Lam will replace Scott Nirenberski who has been CFO since Sept 2020 MT
HEALWELL AI Brief: Appointing Anthony Lam as New Chief Financial Officer MT
Healwell AI Inc. Announces Chief Financial Officer Changes CI
Healwell AI Closes Upsized $20 Million Bought-Deal Private Placement of Share Units MT
Healwell AI Inc. announced that it has received CAD 20.00025 million in funding CI
Healwell AI Subsidiary Partners With Sunnybrook Hospital to Show AI Platform Role in Cancer Staging MT
Healwell AI Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chart Healwell AI Inc.
More charts
HEALWELL AI Inc. is a Canada-based healthcare technology company focused on artificial intelligence (AI) and data science for preventative care. The Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases. The Company's segments include Medical Clinics, Health Technology and Electronic Health Records. It provides government-insured primary and specialty healthcare through medical clinics, technology-enabled rare disease screening, clinical research, pulmonary function testing lab services, AI-driven healthcare information analytics and insights and subscription-based electronic health record information software. Its products include Khure Health, Pentavere, PolyClinic and WELL AI Decision Support. The Company provides clinical information sources and clinical insights. Its clinical information sources include clinical research and trials, lab and diagnostic info, and semi-structured data.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.09 CAD
Average target price
3.95 CAD
Spread / Average Target
+89.00%
Consensus
  1. Stock Market
  2. Equities
  3. AIDX Stock
  4. News Healwell AI Inc.
  5. Healwell AI Agrees to Buy BioPharma Services For $11.9 Million to Expand Clinical Research Offerings